SEC Tracker
Get the app
TCRT · XBRL financial data

Alaunos Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TCRT's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers01*1404*2003*00
Research and development3,656933*126180143(86)*347185469361*427388
General and administrative3,5782,428*1,6179901,007845*747854718549*585564
Total operating expenses8,6647,950*1,7431,1701,150759*1,0941,0391,187910*1,012952
Operating income (loss)(8,664)(7,949)*(1,742)(1,166)(1,150)(755)*(1,092)(1,039)(1,187)(907)*(1,012)(952)
Interest expense00*0000*——————
Other income (expense)188106*60372313*19192814*60
Income tax expense (benefit)—————————year only——
Net income (loss)(8,476)(7,843)*(1,682)(1,129)(1,127)(742)*(1,073)(1,051)(1,159)(893)*(1,006)(952)
Earnings per share, basic USD per share(0.04)—(0.11)(0.71)(0.70)—(0.67)(0.63)(0.55)(0.38)*(0.59)(0.41)
Earnings per share, diluted USD per share(0.04)—(0.11)(0.71)(0.70)—(0.67)(0.63)(0.55)(0.38)*(0.59)(0.41)
Weighted average shares, basic thousands of shares240,046—16,0131,6011,601—1,6011,6762,1832,322*1,9482,432
Weighted average shares, diluted thousands of shares240,046—16,0131,6011,601—1,6011,6762,1832,322*1,9482,432
  • † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 10x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TCRT's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents11,9446,0624,1452,4631,6831,0913192,8791,9381,385354124
Prepaid and other current assets9252,1981,8912,2111,8671,659746857747600616542
Total current assets12,8698,2616,0374,6783,5502,7551,0673,7382,6851,988970666
Property and equipment, net5,53220000——97918274
Right-of-use asset1,0390——————————
Total assets19,4408,2636,0374,6783,5502,7552,1204,7353,7242,9661,8831,516
Accounts payable1,298616597365458516831809843613400732
Accrued liabilities3,0711,34064354236817623126578200195132
Current portion of long-term debt00——————————
Total current liabilities4,6761,9561,2409078266921,0621,074921813595864
Long-term debt—00——0——————
Total liabilities5,5401,9561,2409078266921,0621,074921813595864
Accumulated deficit(907,924)(915,767)(917,449)(918,577)(919,704)(920,446)(921,519)(922,570)(923,729)(924,622)(925,628)(926,580)
Total stockholders' equity13,9006,3074,7973,7712,7242,0631,0583,6612,8032,1531,288652
Total liabilities and equity19,4408,2636,0374,6783,5502,7552,1204,7353,7242,9661,8831,516
Common shares outstanding (cover page) thousands of shares240,62716,01216,0131,6011,6011,6011,6402,1952,2322,37824,4222,540
  • † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 10x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TCRT's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(8,476)(7,843)*(1,682)(1,129)(1,127)(742)*(1,073)(1,051)(1,159)(893)*(1,006)(952)
Stock-based compensation726250*1721018081*68184301243*141246
Net cash from operating activities(6,374)*(7,385)*(1,917)(1,681)*(781)*(592)*(772)(701)*(844)*(552)*(1,031)(300)*
Purchases of property and equipment1*0*00*0*0*———1*——
Net cash from investing activities1*1,503*00*0*0*———(1)*——
Proceeds from issuing common stock0*0*00*0*0*——————
Share repurchases—0*——————————
Repayments of long-term debt0*0*00*0*0*——————
Net cash from financing activities0*0*00*0*0*——0*0*——
Net change in cash(6,373)*(5,882)*(1,917)(1,681)*(781)*(592)*(772)2,560*(941)*(553)*(1,031)(230)*
  • † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 10x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Alaunos Therapeutics1240(300)*2.5M0.4 quarters 10-QJun 30, 2026
BioCardia4,117not reported(1,735)*15.1M2.4 quarters 10-QJun 30, 2026
Raphael Pharmaceutical1not reported0*20.2M— 10-QJun 30, 2026
Traws Pharma5,016not reported(7,504)*15.4M0.7 quarters 10-QJun 30, 2026
Mannatech6,03426,650(792)*1.9M7.6 quarters 10-QJun 30, 2026
Bioxytran177not reported(350)*114.7M0.5 quarters 10-QJun 30, 2026
LeonaBio32,323not reported(16,958)*9.4M3.0 quarters 10-QJun 30, 2026
Artelo Biosciences4,198not reported(5,033)*4.6M0.8 quarters 10-QJun 30, 2026
Oncotelic Therapeutics186250(92)*457.5M2.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.